The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Identification and Characterization of GLP-1 Receptor–Expressing Cells Using a New Transgenic Mouse Model
Open accessAbstract
GLP-1 is an intestinal hormone with widespread actions on metabolism. Therapies based on GLP-1 are highly effective because they increase glucose-dependent insulin secretion in people with type 2 diabetes, but many reports suggest that GLP-1 has additional beneficial or, in some cases, potentially dangerous actions on other tissues, including the heart, vasculature, exocrine pancreas, liver, and central nervous system. Identifying which tissues express the GLP-1 receptor (GLP1R) is critical for the development of GLP-1–based therapies. Our objective was to use a method independent of GLP1R antibodies to identify and characterize the targets of GLP-1 in mice. Using newly generated glp1r-Cre mice crossed with fluorescent reporter strains, we show that major sites of glp1r expression include pancreatic β- and δ-cells, vascular smooth muscle, cardiac atrium, gastric antrum/pylorus, enteric neurones, and vagal and dorsal root ganglia. In the central nervous system, glp1r-fluorescent cells were abundant in the area postrema, arcuate nucleus, paraventricular nucleus, and ventromedial hypothalamus. Sporadic glp1r-fluorescent cells were found in pancreatic ducts. No glp1r-fluorescence was observed in ventricular cardiomyocytes. Enteric and vagal neurons positive for glp1r were activated by GLP-1 and may contribute to intestinal and central responses to locally released GLP-1, such as regulation of intestinal secretomotor activity and appetite.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 also decreases hepatic glucose production by inhibiting glucagon secretion from α cells, and increases insulin sensitivity in skeletal muscle through an indirect mechanism by increasing microvascular recruitment in skeletal muscle which may potentiate local insulin action.7”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 also decreases hepatic glucose production by inhibiting glucagon secretion from α cells, and increases insulin sensitivity in skeletal muscle through an indirect mechanism by increasing microvascular recruitment in skeletal muscle which may potentiate local insulin action.7”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The receptors to these peptides are expressed locally in the gut enteric neurons and vagal afferents, as well as in the central nervous system (CNS), including the brainstem and hypothalamus (De Silva and Bloom, 2012;Richards et al., 2014).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Richards et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1 directly acts on pancreatic β-cells to enhance insulin secretion.”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [7]
In the citing paper
“These cells produce serotonin, glucagon-like peptide-1 (GLP-1), and peptide YY (PYY), affecting brain function and behavior [89,90,136].”
From Unraveling the Connections: Eating Issues, Microbiome, and Gastrointestinal Symptoms in Autism Spectrum Disorder (2025) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 2×
“Reports that DPP4-inactivated GLP-1 triggers vasodilation and that not all responses to GLP-1 are lost in mice lacking glp1r (12) have even led to the speculation that there may exist an alternative receptor responsive to GLP-1 and/or its metabolites.”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Glucose Sensing in L Cells: A Primary Cell Study
Reimann, F., Habib, A. M., Tolhurst, G., Parker, H. E., Rogers, G. J., & Gribble, F. M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.11.002 · Cited by 733 · cited 7×
“L-cells in the epithelium of the small and large intestine (8).”
BackgroundMethodInfluentialSelf-citationFurness, J. B. (2008) · Springer eBooks · doi:10.1007/978-3-540-29678-2_3035 · Cited by 612
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · cited 3×
“The vasodilatory effect of GLP-1 in mice was recently reported to be an indirect consequence of enhanced atrial natriuretic factor release (16).”
BackgroundResultLuche, H., Weber, O., Nageswara Rao, T., Blum, C., & Fehling, H. J. (2007) · European Journal of Immunology · doi:10.1002/eji.200636745 · Cited by 482
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–467 of 467
Toraldo, D. M., Modoni, A. P., Scoditti, E., & Nuccio, F. D. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1429570 · Cited by 2
Antidiabetic potential of capsaicinoids
Piotrowska‐Niczyporuk, A., Jakimiuk, K., Tomczykowa, M., & Tomczyk, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15366-2.00006-x · Cited by 1
Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects
Kim, K. S., Park, J. S., & Choi, H. J. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448320.160 · Cited by 2
Meher, M. M., Afrin, M., Jahan, M. R., Yanai, A., & Islam, M. N. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11347-9 · Cited by 1
Effects of chronic ethanol consumption on brain GLP-1R gene expression in mice and humans
Torregrosa, A. B., García‐Gutiérrez, M. S., Ortuño‐Miquel, S., & Manzanares, J. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03838-5 · Cited by 1
Lin, M.-P., Xue, B.-J., & Bai, X. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-026-10759-7 · Cited by 1
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
Incretin-based therapies for the failing heart
Ussher, J. R., & Campbell, J. E. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000086 · Cited by 1
Axe intestin-cerveau et contrôle du métabolisme glucidique
Abot, A., Murphy, L., & Knauf, C. (2017) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2017.09.004 · Cited by 1
Arterial responses to infusion of glucagon-like peptide-1 in humans: A randomized trial study
Ghanizada, H., Christensen, R. H., Al‐Karagholi, M. A., Elbahi, F. A., Coskun, H., & Ashina, M. (2022) · Peptides · doi:10.1016/j.peptides.2022.170736 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Gut-Derived Hormones—Cardiac Effects of Ghrelin and Glucagon-Like Peptide-1
Ruozi, G., Bortolotti, F., & Recchia, F. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803111-7.00006-3 · Cited by 3
Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice
Zhang, Y., Fava, G. E., Wu, M., Htun, W., Klein, T., Fonseca, V. A., & Wu, H. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00253 · Cited by 1
Wu, L., Qin, Y., Zheng, X., Zhang, G., Zhou, Q., & Liu, L. (2025) · Research Square · doi:10.21203/rs.3.rs-5713487/v1 · Cited by 1
GABA A receptor-mediated synaptic and tonic currents in rat
Korol, S. V., Jin, Z., Babateen, O., & Birnir, B. (2014)
Shamlan, G. H. (2016) · Surrey Research Insight Open Access (The University of Surrey)
van der Wielen, N., & van der (2016)
The role of submucosal neurons in physiological and pathophysiological intestinal secretion
Fung, C. (2016) · Minerva Access (University of Melbourne)
Vergès, B. L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30055-x
Characterization of Novel Glucagon Receptor Interactors that Modify Receptor Activity
Froese, D. S. (2015) · TSpace (University of Toronto)
Neuroendocrine Control of Hepatic Gluconeogenesis
Mao, Z., & Zhang, W. (2017) · InTech eBooks · doi:10.5772/67535
THE ROLE OF THE INTESTINAL MICROBIOTA IN THE MODULATION OF FOOD INTAKE AND BODY WEIGHTPreprint
Dalby, M. J. (2017) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/rqz2p
Ileal Fatty Acid Sensing Mechanisms Regulate Glucose Homeostasis In Vivo
Zadeh‐Tahmasebi, M. (2015) · TSpace (University of Toronto)
The Cardiac Glucagonlike Peptide-1 Receptor: Whither Art Thou?
Brubaker, P. L. (2018) · Endocrinology · doi:10.1210/en.2018-00186
Generation and use of new tools for the characterisation of gut hormone receptors
Biggs, E. K. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.37487
Farr, S. (2017) · TSpace (University of Toronto)
Taher, J. (2017) · TSpace (University of Toronto)
Gadgaard, S., van der Velden, W. J. C., Schiellerup, S. P., Hunt, J. E., Gabe, M., Windeløv, J. A., Boer, G. A., Kissow, H., �rskov, C., Holst, J. J., et al. (2020) · doi:10.22541/au.159818456.67954631
GLP-1R Agonists & Cardiac Energy Metabolism in Type 2 Diabetes
Almutairi, M. G. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-fhr3-cr50
Mulaik, M. W. (2013) · PubMed
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Rosenzweig, S. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727123638.793572332
Суплотова, Л. А., Fedorova, A. I., Kulmametova, D. S., Сергеевна, Д. Т., & Makarova, O. B. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-23-148-155
O’Malley, D. (2023) · Springer eBooks · doi:10.1007/978-3-031-25702-5_10
A mini review on glucagon-like peptide-1 receptor agonists and its role in blood pressure regulationPreprint
Alharbi, N. H. J. (2024) · Preprints.org · doi:10.20944/preprints202402.0005.v1
Spence, D. B., Austin, R. P., Carrol, C., Pierce, S., Richter, D. L., Chamberlain, R., & Schenck, R. C. (2024) · JBJS Journal of Orthopaedics for Physician Assistants · doi:10.2106/jbjs.jopa.24.00005
Krishnan, G., Bagath, M., Devaraj, C., & Soren, N. M. (2024) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2024.114602
Mermet, M., Denom, J., Mieczkowska, A., Biggs, E. K., Gribble, F. M., Reimann, F. M., Magnan, C., Cruciani‐Guglielmacci, C., & Mabilleau, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.05.616809
Self-citationUpdates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004
Role of microbiota-gut-brain axis in obesity on cognitive functions
Gandhi, H., Arora, S., & Sarwat, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21680-0.00015-8
Metabolic connections between Alzheimer's disease and diabetes
Adhikary, K., Ganguly, K., Chowdhury, S. R., & Banerjee, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00024-4
Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension
Aguado, B., Lacoste-Palasset, T., Ruffenach, G., Bauer, F., Savale, L., Humbert, M. J. C., Montani, D., & Antigny, F. (2025) · ERJ Open Research · doi:10.1183/23120541.01479-2025
Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
Kotucha, K., Kapłon, K., Moś, M., Fiegler-Rudol, J., Pietryszyn-Bilińska, A., Dynarowicz, K., Aebisher, D., Wiench, R., & Kawczyk‐Krupka, A. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.24
Malinauskas, M., Stukas, D., Rysevaitė-Kyguolienė, K., Gudaitytė, R., Kupcinskas, L., Casselbrant, A., Jankauskaitė, L., & Maleckas, A. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2025.1734360
Gut-Brain Axis and Microbiome Modulation by Dietary Bioactives
Fazal, S., Gull, S., Sajjad, S., Ismail, N., Sarwat, A., Noor, N., Arshad, H., Ali, R. M., Zafar, A. Q., Shahab, A., et al. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-4139-2.ch005
Gut-brain axis in metabolic control
Singh, S. P., Ghosh, S., Singh, D. K. K., & Sinha, J. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-32848-0.00024-8
A comprehensive review of GLP-1 and aerobic training in cardiovascular disease management
Kordi, N., Kheirandish, R., Akraminia, P., Jung, F., & Karami, S. (2025) · Clinical Hemorheology and Microcirculation · doi:10.1177/13860291251414840
Lobato, C. B., Nielsen, A. B. E., & Holst, J. J. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2025
Semaglutide Prevents Aortic Rupture and Dissection in the Angiotensin II Mouse Model
Ramilo, A. B., Mani, K., Wanhainen, A., Lodén, H., Nilsson, A., Andrén, P. E., Friederich‐Persson, M., & Wågsäter, D. (2026) · Biomedicines · doi:10.3390/biomedicines14040933
Cardiac GLP1R gene expression: A cross-species single-cell transcriptomic analysis
Dostal, C., Ernst, M., Reiner, J., Snelling, R., Hu, C., Pokreisz, P., Kiss, A., & Podesser, B. K. (2026) · Advances in Translational Research · doi:10.1556/1661.2026.00113
Böhm, E. W., Zadeh, J. K., Omran, W., Arad, T., Pfeiffer, N., Wagner, F. M., Patzak, A. R., Oelze, M. W., Daiber, A., Helmstädter, J., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1778848
Guanoliquin, K. P. D. L. C., Juca, D. C. S., Alcocer, Y. P., & Cuadrado, S. P. A. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20262193
Wang, R., Liu, Q., Lu, C., Chen, K., Liu, S., Guo, L., Guo, Z., Liu, Y., & Zhang, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119206
Jin, C. A., Many, G. M., Spurrier, C. S. R., Borsellino, P., Wheeler, M. T., Adkins, J., Snyder, M. P., Newgard, C. B., Radom‐Aizik, S., Cooper, D. M., et al. (2026) · Physiological Genomics · doi:10.1152/physiolgenomics.00171.2026
Gut-liver axis and intestinal microbiota: Key targets of herbal medicines in treatment of MASLD/MASH
Mao, Y., Wei, C., Zhang, Y., Zheng, Y., Ji, R., Ge, L. I. N., He, X., He, Y., Yang, J., & Ma, J. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.08.017
Lee, O., Son, Y., López-Gil, J. F., Rahmati, M., Kang, J., Lee, J.-S., & Yon, D. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71325 · Cited by 1
G-protein-coupled receptors (GPCRs) in the treatment of diabetes
Abirami, P. M., & Ramkumar, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33887-8.00018-0
More than just adipose: the impact of GLP1RA on lean tissue
Julien, M., Jeromson, S., & Wright, D. C. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.90062.2026
Cholesterol Absorption: Mechanisms, Regulation, and Therapeutic Targets
Abdalqadir, N., & Adeli, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27658-3.00059-7
Xie, Z.-Y., Qian, Y., Liu, T.-T., 项平, Mu, Y., & Zhang, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1978397
Metadata
- Authors
- Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F.
- Affiliations
- Addenbrooke's Hospital (GB)
- University College London (GB)
- Corresponding author
- Gribble, Fiona M.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-03-13
- Volume
- 63
- Issue
- 4
- Pages
- 1224-1233
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC4092212
- OpenAlex
- W2146534889
- Cited by
- 472
- References
- 28
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 20 · 2022: 46 · 2021: 49 · 2020: 44 · 2019: 32 · 2018: 47 · 2017: 34 · 2016: 32 · 2015: 33 · 2014: 27
- FWCI
- 24.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Funders
- Wellcome Trust (WT088357Z/09/Z, 088357, WT084210Z/07/Z, 084210)
- Medical Research Council (MR/J013293/2, MR/J013293/1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor, pancreatic beta cells, pancreatic delta cells, enteric neurons, vagal ganglia, dorsal root ganglia, vascular smooth muscle, area postrema, arcuate nucleus, paraventricular nucleus, ventromedial hypothalamus, GLP-1 signaling, appetite regulation, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Central Nervous System, Heart Atria, Islets of Langerhans, Mice, Transgenic, Muscle, Smooth, Vascular, Receptors, Glucagon, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
